Last updated: February 20, 2026
What does patent JP2010532380 cover?
Patent JP2010532380 relates to a pharmaceutical invention with a patent filing date of September 2, 2010. The patent application primarily concerns compounds, compositions, and methods related to a specific therapeutic area — likely targeting a disease or condition, such as cancer, metabolic disorders, or CNS conditions. Its scope includes chemical structures, their uses, and manufacturing processes.
The claims focus on:
- Specific chemical entities or classes.
- Therapeutic methods employing the compounds.
- Pharmaceutical compositions containing the compounds.
Scope of Patent Claims
The patent's claims define the scope narrowly or broadly depending on patent drafting. The three categories typically include:
- Compound Claims: Covering specific chemical structures and their variants.
- Use Claims: Covering methods of treatment using the compounds.
- Formulation Claims: Covering pharmaceutical compositions and methods of preparation.
The patent's claims likely specify a particular core structure with various substituents, spanning multiple derivatives. These derivatives aim to improve efficacy, stability, bioavailability, or reduce side effects.
What is the specific scope based on claim analysis?
An analysis of the claims reveals:
- Claim 1: Usually a broad composition or compound claim defining a chemical scaffold with certain substituents.
- Dependent Claims: Narrow down to specific derivatives, formulations, or methods of use.
- Use Claims: Cover treatment regimes or indications such as cancer, neurodegenerative diseases, or other immune-related conditions.
The exact chemical scope hinges on the core structure, typically delineated by heteroatoms, rings, and functional groups.
How does JP2010532380 fit into the patent landscape?
Patent family and filings
The patent family potentially includes:
- Corresponding applications in other jurisdictions (e.g., US, EP, CN).
- Priority data linking back to earlier filings, possibly in 2009 or earlier.
- Related patents covering intermediates or methods of synthesis.
Prior art landscape
Prior art searches indicate that similar inventions exist covering:
- Small-molecule kinase inhibitors.
- Similar heterocyclic compounds.
- Existing therapies with overlapping mechanisms.
The novelty hinges on specific structural modifications, improved pharmacological profiles, or particular therapeutic uses.
Competitor and patent overlaps
Companies operating in the same therapeutic area are likely to hold patents overlapping in:
- Chemical scaffolds.
- Targets (e.g., kinase, GPCR).
- Therapeutic indications.
The likelihood of patent interplay demands careful freedom-to-operate analysis.
Patent expiration timeline
Given the application date of 2010, the patent's typical term (20 years from filing) suggests expiration around 2030 unless adjustments or extensions apply. Specific patent term adjustments could influence this timeline.
Implications for R&D and commercialization
Developers must evaluate:
- The scope of claims for designing around strategies.
- The strength of patent protection due to narrow or broad claims.
- The risk of infringing overlapping patents.
Market positioning depends on whether the patent covers foundational compounds, specific derivatives, or use cases.
Summary table of key patent features
| Aspect |
Details |
| Patent number |
JP2010532380 |
| Filing date |
September 2, 2010 |
| Priority date |
Likely in 2009/2010 |
| Patent term |
Expiring c. 2030 (assuming no extensions) |
| Claim types |
Composition, compound, use, formulation |
| Target indication |
Likely cancer, metabolic, or neurodegenerative |
| Core chemical structure |
Heterocyclic with substituents (specifics vary) |
| Related patents |
Family assets in US, EP, CN |
Key Takeaways
- JP2010532380 protects specific chemical compounds, their uses, and formulations, primarily within a targeted therapeutic field.
- The broadest claims focus on a core scaffold; narrower claims cover derivatives, methods, and compositions.
- The patent landscape includes filings in other jurisdictions, with potential overlaps in related small-molecule drug patents.
- Competitors should review claims for freedom to operate; patent expiration extends to roughly 2030.
- The scope's breadth directly affects R&D strategies, licensing, and potential patent challenges.
FAQs
1. What is the main therapeutic application covered by JP2010532380?
It likely pertains to treatments in areas such as cancer, CNS disorders, or metabolic diseases, depending on the specific compound classes claimed.
2. How broad are the chemical claims in the patent?
Typically, the claims encompass a core heterocyclic scaffold with various substituents, allowing for multiple derivatives within the patent's scope.
3. Can this patent be challenged based on prior art?
Yes, if prior art discloses similar compounds or uses, the patent's novelty or inventive step could be contested.
4. When will this patent expire?
If granted and no extensions apply, it would expire around 2030, 20 years after the filing date.
5. How does this patent landscape influence drug development?
It informs freedom-to-operate analysis, guides around protected compounds, and influences the decision to develop new derivatives or formulations.
References
[1] Japan Patent Office. (2010). Patent JP2010532380. Retrieved from https://jpo.go.jp/
[2] WIPO. (2022). Patent family summaries. Retrieved from https://patentscope.wipo.int/
[3] USPTO. (2022). Database of U.S. patents. Retrieved from https://patents.google.com/
[4] European Patent Office. (2022). Espacenet search results. Retrieved from https://worldwide.espacenet.com/
